Streetbeat News

Regulatory

META

Donald Trump's potential return to the White House could significantly impact the AI sector, with Deutsche Bank highlighting five major shifts. His relationships with tech leaders like Elon Musk may influence policy, diverging from current administration approaches.

Portfolio Pulse from

November 11, 2024 | 3:15 pm

NVAX

Novavax is set to report its Q3 earnings, with investors keen on updates regarding discussions with the FDA about lifting the clinical hold on its two vaccine programs.

Portfolio Pulse from

November 11, 2024 | 3:00 pm

DIA

SPY

US stocks, including the S&P 500 and Dow, have rallied due to election clarity and potential rate cuts. The upcoming CPI data and Federal Reserve outlook are expected to influence their future performance.

Portfolio Pulse from

November 11, 2024 | 2:45 pm

GNLN

The cannabis industry is gaining popularity, attracting investors despite its volatility. The progress in US legislation has led to a boom in cannabis operators.

Portfolio Pulse from

November 11, 2024 | 2:30 pm

GOOGL

Alphabet is considered significantly undervalued with strong Q3 results and a robust balance sheet. The potential return of the Trump Administration is expected to ease antitrust pressures, creating a favorable environment for Alphabet's growth and innovation.

Portfolio Pulse from

November 11, 2024 | 2:15 pm

DMGGF

DMG Blockchain Solutions has achieved SOC 2 Type II compliance, enhancing its security and regulatory compliance credentials. The company also purchased its first tranche of hydro miners.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

NVAX

The U.S. FDA has lifted its clinical hold on Novavax's late-stage trial for its COVID-influenza combo and standalone flu vaccines, allowing the company to proceed with its trials.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

NVAX

Levi & Korsinsky has initiated an investigation into Novavax, Inc. (NVAX) for potential violations of federal securities laws. This follows the FDA's clinical hold on Novavax's combination influenza and Covid-19 shot and its stand-alone influenza vaccine.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

BNZI

NDAQ

Banzai International, Inc. has regained compliance with Nasdaq's minimum market value of publicly held shares requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from

November 11, 2024 | 1:45 pm

NVAX

The U.S. FDA has lifted the clinical hold on Novavax's COVID-19-Influenza combination and stand-alone influenza vaccine trials, allowing the company to proceed with its Phase 3 trials.

Portfolio Pulse from

November 11, 2024 | 1:45 pm